Introduktion
Den här sidan ger en omfattande analys av den kända insiderhandelshistoriken för Christopher Richard Anzalone. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. Det är olagligt för insiders att göra affärer i sina företag baserat på specifik, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4. Trots dessa restriktioner tyder akademisk forskning på att insiders – i allmänhet – tenderar att överträffa marknaden i sina egna företag.
Genomsnittlig handelslönsamhet
Den genomsnittliga handelslönsamheten är den genomsnittliga avkastningen av alla köp på den öppna marknaden som insidern gjort under de senaste tre åren. För att beräkna detta undersöker vi alla oplanerade köp på öppen marknad som görs av insidern, exklusive alla affärer som markerats som en del av en 10b5-1-handelsplan. Vi beräknar sedan den genomsnittliga prestandan för dessa affärer under 3, 6 och 12 månader, med ett genomsnitt av var och en av dessa varaktigheter för att generera ett slutgiltigt resultatmått för varje affär. Slutligen tar vi ett genomsnitt av alla prestationsmått för att beräkna ett prestationsmått för insidern. Denna lista inkluderar endast insiders som har gjort minst tre affärer under de senaste två åren.
Om lönsamheten för denna insiderhandel är "N/A", så har insidern antingen inte gjort några köp på den öppna marknaden under de senaste tre åren, eller så är affärerna de har gjort för nya för att kunna beräkna ett tillförlitligt resultatmått.
Uppdateringsfrekvens: Dagligen
Företag med rapporterade insiderpositioner
SEC-anmälningarna visar att Christopher Richard Anzalone har rapporterat innehav eller affärer i följande företag:
Värdepapper | Titel | Senaste rapporterade innehav |
---|---|---|
US:ARWR / Arrowhead Pharmaceuticals, Inc. | Chief Executive Officer, Director | 3 921 255 |
Hur man tolkar diagrammen
Följande diagram visar aktieutvecklingen för värdepapper efter varje icke-planerad handel på öppen marknad som görs av Christopher Richard Anzalone. Icke-planerad handel är affärer som inte gjordes som en del av en 10b5-1-handelsplan. Aktieutvecklingen visas som kumulativ procentuell förändring av aktiekursen. Till exempel, om en insiderhandel gjordes den 1 januari 2019, kommer diagrammet att visa den dagliga procentuella förändringen av värdepapperet fram till idag. Om aktiekursen skulle gå från $10 till $15 under denna tid, skulle den kumulativa procentuella förändringen i aktiekursen vara 50%. En förändring i priset från 10 USD till 20 USD skulle vara 100 % och en prisändring på 10 USD till 5 USD skulle vara -50 %.
I slutändan försöker vi avgöra hur nära insiders affärer korrelerar med överavkastning (positiv eller negativ) i aktiekursen för att se om insidern tar tid för sina affärer att dra nytta av insiderinformation. Tänk på situationen där en insider gjorde detta. I den här situationen förväntar vi oss antingen (a) positiv avkastning efter köp eller (b) negativ avkastning efter försäljning. I fallet med (a) skulle KÖP-diagrammet visa en serie uppåtlutande kurvor, vilket indikerar positiv avkastning efter varje köptransaktion. I fallet med (b) skulle SALE-diagrammet visa en serie nedåtlutande kurvor, vilket indikerar negativ avkastning efter varje försäljningstransaktion.
Detta är dock inte tillräckligt för att dra slutsatser. Om till exempel aktiekursen i bolaget var i en icke-cyklisk stigning under många år, skulle vi förvänta oss att alla tomter efter köpet skulle vara uppåtlutande. Likaså skulle icke-cykliska nedgångar under många år resultera i nedåtlutande post-trade tomter. Inget av dessa diagram skulle tyda på insiderhandel.
Den starkaste indikatorn skulle vara en situation där aktiekursen var extremt cyklisk, och det fanns både positiva signaler i KÖP-diagrammet och negativa plotter på SALE-diagrammet. Denna situation skulle i hög grad tyda på en insider som tog tid för affärer till sin ekonomiska fördel.
Insiderhandelshistorik
Den här tabellen visar den fullständiga listan över insideraffärer gjorda av Christopher Richard Anzalone som avslöjats för Securities Exchange Commission (SEC).
Fildatum | Transaktionsdatum | Schema | Ticker | Värdepapper | Kode | Aktier | Återstående aktier | Procentuell förandring | Aktie pris |
Transaktionsvärde | Återstående värde |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-04-11 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −50 800 | 3 921 255 | −1,28 | 11,49 | −583 692 | 45 055 220 | |
2025-04-11 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −50 000 | 3 972 055 | −1,24 | 10,87 | −543 500 | 43 176 238 | |
2025-04-11 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −1 617 | 4 022 055 | −0,04 | 11,76 | −19 016 | 47 299 367 | |
2025-04-11 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −3 400 | 4 023 672 | −0,08 | 10,75 | −36 550 | 43 254 474 | |
2025-04-11 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −35 305 | 4 027 072 | −0,87 | 9,93 | −350 579 | 39 988 825 | |
2025-03-17 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −51 425 | 4 062 377 | −1,25 | 15,07 | −774 975 | 61 220 021 | |
2025-03-17 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
A - Award | 340 000 | 4 113 802 | 9,01 | ||||
2025-03-05 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −133 333 | 3 773 802 | −3,41 | 17,02 | −2 269 328 | 64 230 110 |
2025-03-05 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 133 333 | 4 073 802 | 3,38 | 7,75 | 1 033 331 | 31 571 966 | |
2025-03-05 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −166 667 | 3 907 135 | −4,09 | 18,03 | −3 005 006 | 70 445 644 |
2025-03-05 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 166 667 | 3 940 469 | 4,42 | 7,75 | 1 291 669 | 30 538 635 | |
2025-02-10 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
A - Award | 9 550 | 3 773 802 | 0,25 | 20,10 | 191 955 | 75 853 420 | |
2025-01-06 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −11 520 | 3 764 252 | −0,31 | 19,05 | −219 456 | 71 709 001 |
2024-12-23 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −12 563 | 3 775 772 | −0,33 | 19,59 | −246 109 | 73 967 373 |
2024-12-20 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
A - Award | 100 000 | 3 788 335 | 2,71 | ||||
2024-12-20 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −5 799 | 3 688 335 | −0,16 | 22,12 | −128 274 | 81 585 970 |
2024-12-20 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −8 260 | 3 694 134 | −0,22 | 21,74 | −179 572 | 80 310 473 |
2024-12-20 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −12 653 | 3 702 394 | −0,34 | 20,52 | −259 640 | 75 973 125 |
2024-02-02 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −19 730 | 3 715 048 | −0,53 | 32,71 | −645 368 | 121 519 220 |
2024-02-02 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −37 769 | 3 734 778 | −1,00 | 32,16 | −1 214 651 | 120 110 460 |
2024-02-02 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 57 499 | 3 772 547 | 1,55 | 14,54 | 836 035 | 54 852 833 |
2024-01-04 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −5 318 | 3 715 048 | −0,14 | 31,25 | −166 188 | 116 095 250 |
2024-01-04 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −4 634 | 3 720 366 | −0,12 | 30,74 | −142 449 | 114 364 051 |
2023-12-22 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −12 000 | 3 725 000 | −0,32 | 28,54 | −342 480 | 106 311 500 |
2023-10-27 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −24 338 | 3 737 000 | −0,65 | 24,21 | −589 223 | 90 472 770 |
2023-09-20 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −26 232 | 3 761 338 | −0,69 | 28,27 | −741 579 | 106 333 025 |
2023-09-20 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −31 523 | 3 787 570 | −0,83 | 28,00 | −882 644 | 106 051 960 |
2023-09-20 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 57 755 | 3 819 093 | 1,54 | 4,75 | 274 336 | 18 140 692 |
2023-05-05 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −25 992 | 3 761 338 | −0,69 | 40,02 | −1 040 200 | 150 528 747 | |
2023-05-05 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −24 008 | 3 787 330 | −0,63 | 38,97 | −935 592 | 147 592 250 | |
2023-05-05 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 50 000 | 3 811 338 | 1,33 | 2,01 | 100 500 | 7 660 789 | |
2023-05-05 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −54 928 | 3 761 338 | −1,44 | 39,14 | −2 149 882 | 147 218 769 | |
2023-05-05 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 54 928 | 3 816 266 | 1,46 | 2,01 | 110 405 | 7 670 695 | |
2022-12-20 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
A - Award | 234 025 | 3 720 714 | 6,71 | ||||
2022-12-20 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
A - Award | 18 375 | 3 486 689 | 0,53 | ||||
2022-09-29 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | −1 542 | 3 468 314 | −0,04 | 31,21 | −48 126 | 108 246 080 |
2022-09-29 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | −39 082 | 3 469 856 | −1,11 | 30,77 | −1 202 553 | 106 767 469 |
2022-07-12 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
D - Sale to Issuer | −551 197 | 3 508 938 | −13,58 | ||||
2022-07-11 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 2 501 | 4 060 135 | 0,06 | 14,54 | 36 365 | 59 034 363 | |
2022-02-14 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy Common Stock) |
M - Exercise | −146 388 | 615 033 | −19,23 | ||||
2022-02-14 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 900 | 4 057 634 | −0,05 | 50,51 | −95 969 | 204 951 093 |
2022-02-14 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −61 482 | 4 059 534 | −1,49 | 50,90 | −3 129 434 | 206 630 281 |
2022-02-14 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −42 153 | 4 121 016 | −1,01 | 52,28 | −2 203 759 | 215 446 716 |
2022-02-14 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −40 853 | 4 163 169 | −0,97 | 53,11 | −2 169 703 | 221 105 906 |
2022-02-14 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 146 388 | 4 204 022 | 3,61 | 5,19 | 759 754 | 21 818 874 |
2022-01-07 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy Common Stock) |
M - Exercise | −11 806 | 761 421 | −1,53 | ||||
2022-01-07 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 11 806 | 4 057 634 | 0,29 | 5,19 | 61 273 | 21 059 120 | |
2022-01-04 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
A - Award | 800 000 | 4 045 828 | 24,65 | ||||
2021-12-23 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy Common Stock) |
M - Exercise | −11 806 | 773 227 | −1,50 | ||||
2021-12-23 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 11 806 | 3 245 828 | 0,37 | 5,19 | 61 273 | 16 845 847 | |
2021-12-17 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −6 989 | 3 219 022 | −0,22 | 70,19 | −490 558 | 225 943 154 |
2021-12-17 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −9 223 | 3 226 011 | −0,29 | 69,52 | −641 183 | 224 272 285 |
2021-12-17 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −3 074 | 3 235 234 | −0,09 | 68,20 | −209 647 | 220 642 959 |
2021-12-17 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −14 857 | 3 238 308 | −0,46 | 67,19 | −998 242 | 217 581 915 |
2021-12-17 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −25 857 | 3 253 165 | −0,79 | 66,28 | −1 713 802 | 215 619 776 |
2021-10-22 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −5 830 | 3 279 022 | −0,18 | 66,09 | −385 305 | 216 710 564 |
2021-10-22 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −44 170 | 3 284 852 | −1,33 | 65,57 | −2 896 227 | 215 387 746 |
2021-10-22 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −15 000 | 3 329 022 | −0,45 | 66,23 | −993 450 | 220 481 127 |
2021-01-04 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
A - Award | 800 000 | 3 344 022 | 31,45 | ||||
2021-01-04 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
G - Gift | −599 | 2 544 022 | −0,02 | ||||
2020-12-30 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
G - Gift | −1 126 | 2 544 621 | −0,04 | ||||
2020-12-22 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock (right to buy) |
M - Exercise | −28 274 | 800 033 | −3,41 | ||||
2020-12-22 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock (right to buy) |
M - Exercise | −12 236 | 828 307 | −1,46 | ||||
2020-12-22 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 28 274 | 2 545 747 | 1,12 | 6,15 | 173 885 | 15 656 344 | |
2020-12-22 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 12 236 | 2 517 473 | 0,49 | 4,75 | 58 121 | 11 957 997 | |
2020-12-10 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −38 676 | 840 543 | −4,40 | ||||
2020-12-10 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −4 003 | 2 505 237 | −0,16 | 71,61 | −286 655 | 179 400 022 | |
2020-12-10 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −5 880 | 2 509 240 | −0,23 | 70,87 | −416 716 | 177 829 839 | |
2020-12-10 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −12 067 | 2 515 120 | −0,48 | 69,80 | −842 277 | 175 555 376 | |
2020-12-10 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −16 726 | 2 527 187 | −0,66 | 67,27 | −1 125 158 | 170 003 869 | |
2020-12-10 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 38 676 | 2 543 913 | 1,54 | 2,01 | 77 739 | 5 113 265 | |
2020-12-10 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −16 324 | 879 219 | −1,82 | ||||
2020-12-10 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −16 324 | 2 505 237 | −0,65 | 67,97 | −1 109 542 | 170 280 959 | |
2020-12-10 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 16 324 | 2 521 561 | 0,65 | 2,01 | 32 811 | 5 068 338 | |
2020-10-23 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −12 272 | 2 505 237 | −0,49 | 58,57 | −718 771 | 146 731 731 |
2020-10-23 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −87 728 | 2 517 509 | −3,37 | 58,16 | −5 102 260 | 146 418 323 |
2020-08-14 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −50 000 | 895 543 | −5,29 | ||||
2020-08-14 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −50 000 | 2 605 237 | −1,88 | 41,35 | −2 067 500 | 107 726 550 | |
2020-08-14 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 50 000 | 2 655 237 | 1,92 | 9,90 | 495 000 | 26 286 846 | |
2020-06-26 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −23 | 2 605 237 | 0,00 | 39,55 | −910 | 103 037 123 | |
2020-06-26 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −99 977 | 2 605 260 | −3,70 | 38,81 | −3 880 107 | 101 110 141 | |
2020-01-03 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
A - Award | 900 000 | 2 705 237 | 49,85 | ||||
2019-12-27 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −83 333 | 1 805 237 | −4,41 | 63,50 | −5 291 646 | 114 632 550 | |
2019-12-13 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −3 393 | 1 888 570 | −0,18 | 68,18 | −231 335 | 128 762 703 |
2019-12-13 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −25 412 | 1 891 963 | −1,33 | 67,30 | −1 710 228 | 127 329 110 |
2019-12-13 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −45 577 | 1 917 375 | −2,32 | 66,47 | −3 029 503 | 127 447 916 |
2019-12-13 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −8 951 | 1 962 952 | −0,45 | 65,85 | −589 423 | 129 260 389 |
2019-12-13 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −8 379 | 1 971 903 | −0,42 | 69,41 | −581 586 | 136 869 787 |
2019-12-13 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −10 343 | 1 980 282 | −0,52 | 68,51 | −708 599 | 135 669 120 |
2019-12-13 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −58 059 | 1 990 625 | −2,83 | 67,31 | −3 907 951 | 133 988 969 |
2019-12-13 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −23 219 | 2 048 684 | −1,12 | 66,82 | −1 551 494 | 136 893 065 |
2019-12-04 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −8 022 | 2 071 903 | −0,39 | 62,00 | −497 364 | 128 457 986 |
2019-12-04 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −4 011 | 2 079 925 | −0,19 | 60,73 | −243 588 | 126 313 845 |
2019-12-04 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −3 656 | 2 083 936 | −0,18 | 72,95 | −266 705 | 152 023 131 |
2019-12-04 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −3 800 | 2 087 592 | −0,18 | 72,13 | −274 094 | 150 578 011 |
2019-12-04 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −2 448 | 2 091 392 | −0,12 | 70,72 | −173 123 | 147 903 242 |
2019-12-04 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −6 617 | 2 093 840 | −0,32 | 69,50 | −459 882 | 145 521 880 |
2019-12-04 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −8 510 | 2 100 457 | −0,40 | 68,50 | −582 935 | 143 881 304 |
2019-12-04 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −7 193 | 2 108 967 | −0,34 | 67,63 | −486 463 | 142 629 438 |
2019-12-04 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −5 743 | 2 116 160 | −0,27 | 66,58 | −382 369 | 140 893 933 |
2019-10-11 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −56 325 | 945 543 | −5,62 | ||||
2019-10-11 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −56 325 | 2 121 903 | −2,59 | 31,83 | −1 792 825 | 67 540 172 | |
2019-10-11 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 56 325 | 2 178 228 | 2,65 | 5,20 | 292 890 | 11 326 786 | |
2019-09-27 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −20 000 | 2 121 903 | −0,93 | 28,25 | −565 000 | 59 943 760 | |
2019-09-24 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −66 645 | 1 001 868 | −6,24 | ||||
2019-09-24 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −12 673 | 2 141 903 | −0,59 | 29,04 | −368 024 | 62 200 863 | |
2019-09-24 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −53 972 | 2 154 576 | −2,44 | 28,00 | −1 511 216 | 60 328 128 | |
2019-09-24 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 66 645 | 2 208 548 | 3,11 | 5,10 | 339 890 | 11 263 595 | |
2019-09-24 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −41 755 | 1 068 513 | −3,76 | ||||
2019-09-24 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −41 755 | 2 141 903 | −1,91 | 29,04 | −1 212 565 | 62 200 863 | |
2019-09-24 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 41 755 | 2 183 658 | 1,95 | 5,10 | 212 950 | 11 136 656 | |
2019-09-24 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −4 250 | 1 110 268 | −0,38 | ||||
2019-09-24 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −4 250 | 2 141 903 | −0,20 | 29,00 | −123 250 | 62 115 187 | |
2019-09-24 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 4 250 | 2 146 153 | 0,20 | 5,10 | 21 675 | 10 945 380 | |
2019-05-29 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −9 376 | 1 133 418 | −0,82 | ||||
2019-05-29 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −40 072 | 1 142 794 | −3,39 | ||||
2019-05-29 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 9 376 | 2 141 903 | 0,44 | 2,62 | 24 565 | 5 611 786 | |
2019-05-29 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 40 072 | 2 132 527 | 1,92 | 2,01 | 80 545 | 4 286 379 | |
2019-04-05 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −50 000 | 2 092 455 | −2,33 | 19,30 | −965 000 | 40 384 382 | |
2019-01-03 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
A - Award | 600 000 | 2 142 455 | 38,90 | ||||
2018-12-21 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −90 000 | 1 542 455 | −5,51 | 13,92 | −1 252 800 | 21 470 974 |
2018-12-14 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common STock |
S - Sale | X | −90 000 | 1 632 455 | −5,23 | 14,07 | −1 266 300 | 22 968 642 |
2018-11-09 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −5 300 | 1 722 455 | −0,31 | 14,95 | −79 235 | 25 750 702 |
2018-11-09 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −76 200 | 1 727 755 | −4,22 | 14,35 | −1 093 470 | 24 793 284 |
2018-09-05 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −64 834 | 1 803 955 | −3,47 | 14,45 | −936 851 | 26 067 150 |
2018-09-05 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −100 000 | 1 868 789 | −5,08 | 14,45 | −1 445 000 | 27 004 001 |
2018-03-16 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −26 000 | 1 968 789 | −1,30 | 7,40 | −192 400 | 14 569 039 |
2018-03-15 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −100 000 | 1 994 789 | −4,77 | 7,41 | −741 000 | 14 781 386 |
2018-03-15 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −100 000 | 2 094 789 | −4,56 | 7,44 | −744 000 | 15 585 230 |
2018-03-15 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −100 000 | 2 194 789 | −4,36 | 7,43 | −743 000 | 16 307 282 |
2018-01-03 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
A - Award | 500 000 | 2 294 789 | 27,86 | ||||
2017-04-14 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
A - Award | 978 000 | 1 794 789 | 119,74 | ||||
2016-12-15 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −300 444 | 816 789 | −26,89 | 1,27 | −381 564 | 1 037 322 | |
2016-07-05 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock Warrant |
X - Other | −15 772 | 0 | −100,00 | ||||
2016-07-05 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 15 772 | 1 117 233 | 1,43 | 5,09 | 80 279 | 5 686 716 | |
2016-01-04 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Stock Options |
A - Award | 80 000 | 1 166 466 | 7,36 | ||||
2016-01-04 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Common Stock |
A - Award | 540 000 | 1 101 461 | 96,18 | ||||
2016-01-04 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Common Stock |
F - Taxes | −58 712 | 561 461 | −9,47 | 6,13 | −359 905 | 3 441 756 | |
2015-03-06 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Stock Options |
A - Award | 300 000 | 1 086 466 | 38,15 | ||||
2015-03-06 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Common Stock |
A - Award | 360 000 | 620 173 | 138,37 | ||||
2014-10-15 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Common Stock |
P - Purchase | 16 000 | 260 173 | 6,55 | 6,32 | 101 120 | 1 644 293 | |
2014-10-15 |
|
4/A | ARWR |
ARROWHEAD RESEARCH CORP
Common Stock |
P - Purchase | 16 000 | 260 173 | 6,55 | 6,32 | 101 120 | 1 644 293 | |
2014-02-10 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Stock Options |
A - Award | 60 000 | 786 466 | 8,26 | ||||
2014-02-10 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Common Stock |
A - Award | 210 000 | 244 173 | 614,52 | ||||
2013-09-24 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Stock Option |
A - Award | 69 991 | 726 466 | 10,66 | ||||
2013-05-08 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Stock Option |
A - Award | 200 000 | 656 475 | 43,81 | ||||
2012-10-02 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Stock Option |
A - Award | 50 000 | 456 475 | 12,30 | ||||
2012-02-21 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Stock Option |
A - Award | 170 000 | 406 475 | 71,89 |